BT-001 in combination with pembrolizumab is well tolerated and shows sustained antitumoral activity in both injected and non-injected lesions Data support further development of BT-001 in solid tumors ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback